New-Onset Psychotic Symptoms Following Abrupt Buprenorphine/Naloxone Discontinuation in a Female Patient with Bipolar Disorder: A Case Report

dc.contributor.authorLin, Yezheen
dc.contributor.authorZhang, Alexander D.en
dc.contributor.authorSun, Ching-Fangen
dc.contributor.authorWhite, Justin B.en
dc.contributor.authorQi, Ansien
dc.contributor.authorFarrell, Jessica A.en
dc.contributor.authorTrestman, Robert L.en
dc.contributor.authorMartin, Rachel K.en
dc.contributor.authorKablinger, Anita S.en
dc.date.accessioned2023-02-07T13:02:34Zen
dc.date.available2023-02-07T13:02:34Zen
dc.date.issued2022en
dc.date.updated2023-02-06T22:15:39Zen
dc.description.abstractBuprenorphine and naloxone (Suboxone) is a combination medication-assisted treatment (MAT) for opioid use disorder. MAT withdrawal-induced psychosis is a rare clinical presentation. To our best knowledge, only three reports have summarized the characteristic manifestations of buprenorphine withdrawal psychosis, yet all of them were male. In this case report, we present a 41-year-old female patient with bipolar disorder and comorbid substance use disorder who developed new-onset psychosis and relapse of manic symptoms following abrupt discontinuation of Suboxone. Manic and psychotic symptoms remitted after a short-term hospitalization with the treatment of an antipsychotic and a mood stabilizer. In addition to discussing this case presentation and treatment approach, we review existing literature and discuss possible underlying mechanisms to enhance understanding of this clinical phenomenon. Psychopharmacology Bulletin.en
dc.description.versionAccepted versionen
dc.format.extentPages 72-80en
dc.format.mimetypeapplication/pdfen
dc.identifier.eissn2472-2448en
dc.identifier.issn0048-5764en
dc.identifier.issue3en
dc.identifier.orcidKablinger, Anita [0000-0002-7131-0036]en
dc.identifier.orcidTrestman, Robert [0000-0003-0168-8057]en
dc.identifier.pmid35815178en
dc.identifier.urihttp://hdl.handle.net/10919/113692en
dc.identifier.volume52en
dc.language.isoenen
dc.relation.urihttps://www.ncbi.nlm.nih.gov/pubmed/35815178en
dc.rightsIn Copyrighten
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/en
dc.subjectbuprenorphineen
dc.subjectmaniaen
dc.subjectpsychosisen
dc.subjectsubstance-withdrawalen
dc.subjecttwo-hit hypothesisen
dc.subjectClinical Researchen
dc.subjectClinical Trials and Supportive Activitiesen
dc.subjectMental Healthen
dc.subjectSerious Mental Illnessen
dc.subjectDrug Abuse (NIDA Only)en
dc.subjectBehavioral and Social Scienceen
dc.subjectPreventionen
dc.subjectBrain Disordersen
dc.subjectNeurosciencesen
dc.subjectSubstance Abuseen
dc.subject3 Good Health and Well Beingen
dc.subject.meshHumansen
dc.subject.meshSubstance Withdrawal Syndromeen
dc.subject.meshBuprenorphineen
dc.subject.meshNaloxoneen
dc.subject.meshAntipsychotic Agentsen
dc.subject.meshBipolar Disorderen
dc.subject.meshPsychotic Disordersen
dc.subject.meshAdulten
dc.subject.meshFemaleen
dc.subject.meshMaleen
dc.subject.meshBuprenorphine, Naloxone Drug Combinationen
dc.titleNew-Onset Psychotic Symptoms Following Abrupt Buprenorphine/Naloxone Discontinuation in a Female Patient with Bipolar Disorder: A Case Reporten
dc.title.serialPsychopharmacology Bulletinen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
dc.type.otherJournal Articleen
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/Faculty of Health Sciencesen
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicineen
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicine/Psychiatry and Behavioral Medicineen
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicine/Psychiatry and Behavioral Medicine/Psychiatry and Behavioral Medicineen
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicine/TEACH Membersen

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
72-80_PB-52-3-2022-Lin.pdf
Size:
273.77 KB
Format:
Adobe Portable Document Format
Description:
Accepted version